-
公开(公告)号:ES2872555T3
公开(公告)日:2021-11-02
申请号:ES16813437
申请日:2016-06-23
Applicant: UNIV HEALTH NETWORK
Inventor: SAMPSON PETER BRENT , PATEL NARENDRA KUMAR B , PAULS HEINZ W , LI SZE-WAN , NG GRACE , LAUFER RADOSLAW , LIU YONG , LANG YUNHUI
IPC: C07D495/04 , A61K31/4355 , A61K31/4436 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/5355 , A61K31/5377 , A61K31/551 , A61K39/00 , A61K39/395 , A61K45/06 , A61P35/00 , C07K16/28
Abstract: Un compuesto representado por la fórmula (I-A): **(Ver fórmula)** o una sal farmacéuticamente aceptable del mismo, en el que: R es H, -F, -CI, -Br, -OH, -alquilo (C1-C4), -haloalquilo (C1-C4), -alcoxilo (C1-C4), -alquilen (C1-C4)-OH o heterociclilo monocíclico de 4-7 miembros opcionalmente sustituido con 1-3 grupos seleccionados de -F, - CI, -Br, -OH, -alquilo (C1-C4), -haloalquilo (C1-C4) o -alcoxilo (C1-C4); R1 es -NRaRb o -ORa1; Ra en cada aparición es independientemente -H, -alquilo (C1-C6), -(CH2)n-cicloalquilo (C3-C7), -(CH2)n- heterociclilo monocíclico de 3-7 miembros, -(CH2)n-cicloalquilo (C6-C12) en puente, -(CH2)n-heteroarilo de 5- 10 miembros opcionalmente sustituido; o -(CH2)n-heterociclilo en puente de 6-12 miembros, en el que el - alquilo (C1-C6), -(CH2)n-cicloalquilo (C3-C7), -(CH2)n-heterociclilo monocíclico de 3-7 miembros, -(CH2)n- cicloalquilo (C6-C12) en puente, -(CH2)n-heteroarilo de 5-10 miembros o -(CH2)n-heterociclilo en puente de 6- 12 miembros está opcionalmente sustituido con 1-3 grupos seleccionados de -F, -CI, -Br, -CN, -NH2, -OH, oxo, -alquilo (C1-C4), -haloalquilo (C1-C4), -alcoxilo (C1-C4), -haloalcoxilo (C1-C4), -alquilen (C1-C4)-OH o - alquilen (C1-C4)-NH2; Rb en cada aparición es independientemente -H o -alquilo (C1-C6); o Ra y Rb, junto con el nitrógeno al que están unidos, forman -heterociclilo (C3-C10); Ra1 en cada aparición es independientemente -H, alquilo (C1-C6), cicloalquilo (C3-C10), heterociclilo de 3-10 miembros, arilo (C6-C10) o heteroarilo de 3-10 miembros; R4 y R5, junto con el nitrógeno al que están unidos, forman heterociclilo monocíclico de 4-7 miembros o heterociclilo en puente de 6-12 miembros, en el que el heterociclilo monocíclico de 4-7 miembros o heterociclilo en puente de 6-12 miembros está opcionalmente sustituido con 1-3 grupos seleccionados de - F, -CI, -Br, -CN, -NH2, -OH, oxo, -alquilo (C1-C4), -haloalquilo (C1-C4), -alcoxilo (C1-C4), -haloalcoxilo (C1-C4), -alquilen (C1-C4)-OH o -alquilen (C1-C4)-NH2; R6 en cada aparición es independientemente -F, -CI, -Br, -CN, -NH2, -OH, -alquilo (C1-C6), - haloalquilo (C1- C6), -alquenilo (C2-C6), -alquinilo (C2-C6), cicloalquilo (C3-C6), -alcoxilo (C1-C6), -haloalcoxilo (C1-C6), - alquilen (C1-C6)-OH o -alquilen (C1-C6)-NH2; m es 0, 1, 2 o 3; y n es 0, 1 o 2.
-
公开(公告)号:SG10202105964RA
公开(公告)日:2021-07-29
申请号:SG10202105964R
申请日:2016-06-23
Applicant: UNIV HEALTH NETWORK
Inventor: SAMPSON PETER BRENT , PATEL NARENDRA KUMAR B , PAULS HEINZ W , LI SZE-WAN , NG GRACE , LAUFER RADOSLAW , LIU YONG , LANG YUNHUI
Abstract: Thienopyridinone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. In these compounds, one of X1; X2, and X3 is S and the other two are each independently CR, wherein R and all other variables are as defined herein. The compounds are shown to inhibit HPK1 kinase activity and to have in vivo antitumor activity. The compounds can be effectively combined with pharmaceutically acceptable carriers and also with other immunomodulatory approaches, such as a checkpoint inhibition or inhibitors of tryptophan oxidation. Formula (I).
-
公开(公告)号:SG10202103332UA
公开(公告)日:2021-05-28
申请号:SG10202103332U
申请日:2017-07-13
Applicant: UNIV HEALTH NETWORK
Inventor: LI SZE-WAN , PAULS HEINZ W , SAMPSON PETER BRENT
Abstract: The present invention relates to a novel co-crystal of the compound of formula (I):wherein the co-former molecule is bisphosphate hemihydrate, to processes for the preparation of the co-crystal, to pharmaceutical compositions containing the co-crystal, to the use of such a co-crystal in the manufacture of a medicament for use in the treatment of cancer and to methods of treating such diseases in the human or animal body by administering a therapeutically effective amount of such a co-crystal.
-
公开(公告)号:DK3322711T3
公开(公告)日:2021-04-26
申请号:DK16813437
申请日:2016-06-23
Applicant: UNIV HEALTH NETWORK
Inventor: SAMPSON PETER BRENT , PATEL NARENDRA KUMAR B , PAULS HEINZ W , LI SZE-WAN , NG GRACE , LAUFER RADOSLAW , LIU YONG , LANG YUNHUI
IPC: C07D495/04 , A61K31/4355 , A61K31/4436 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/5355 , A61K31/5377 , A61K31/551 , A61K39/00 , A61K39/395 , A61K45/06 , A61P35/00 , C07K16/28
-
公开(公告)号:HK1255833A1
公开(公告)日:2019-08-30
申请号:HK18114909
申请日:2018-11-21
Applicant: UNIV HEALTH NETWORK
Inventor: SAMPSON PETER BRENT , PATEL NARENDRA KUMAR B , PAULS HEINZ W , LI SZE-WAN , NG GRACE , LAUFER RADOSLAW , LIU YONG , LANG YUNHUI
IPC: C07D20060101 , A61K20060101 , A61P20060101 , C07K20060101
-
公开(公告)号:ES2718603T3
公开(公告)日:2019-07-03
申请号:ES14854037
申请日:2014-10-17
Applicant: UNIV HEALTH NETWORK
Inventor: SAMPSON PETER BRENT , FEHER MIKLOS , PAULS HEINZ W
IPC: C07D413/14 , A61K31/5377 , A61P35/00
-
公开(公告)号:CA2850394C
公开(公告)日:2019-05-21
申请号:CA2850394
申请日:2012-10-12
Applicant: UNIV HEALTH NETWORK
Inventor: PAULS HEINZ W , LAUFER RADOSLAW , LIU YONG , LI SZE-WAN , FORREST BRYAN T , LANG YUNHUI , PATEL NARENDRA KUMAR B , EDWARDS LOUISE G , SAMPSON PETER BRENT , FEHER MIKLOS , AWREY DONALD E , NG GRACE
IPC: C07D401/00 , A61K31/416 , A61P35/00 , C07D231/56 , C07D401/02 , C07D401/14 , C07D403/02 , C07D405/14 , C07D409/14 , C07D451/06 , C07D491/107
Abstract: The present teaching provide indazole compounds represented by Structural Formulae (I) or (I') or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as TTK protein kinase, polo-like kinase 4 (PLK4) and Aurora kinases having anticancer activity against breast cancer cells, colon cancer cells, and ovarian cancer cells.
-
公开(公告)号:HRP20190564T1
公开(公告)日:2019-05-17
申请号:HRP20190564
申请日:2019-03-22
Applicant: UNIV HEALTH NETWORK
Inventor: SAMPSON PETER BRENT , FEHER MIKLOS , PAULS HEINZ W
IPC: C07D413/14 , A61K31/5377 , A61P35/00
-
公开(公告)号:RS58413B1
公开(公告)日:2019-04-30
申请号:RSP20190269
申请日:2014-10-17
Applicant: UNIV HEALTH NETWORK
Inventor: SAMPSON PETER BRENT , FEHER MIKLOS , PAULS HEINZ W
IPC: C07D413/14 , A61K31/5377 , A61P35/00
-
公开(公告)号:AU2017299850A8
公开(公告)日:2019-03-21
申请号:AU2017299850
申请日:2017-07-13
Applicant: UNIV HEALTH NETWORK
Inventor: LI SZE-WAN , PAULS HEINZ W , SAMPSON PETER BRENT
IPC: C07D487/04 , A61K31/519 , A61P35/00 , C30B7/02
Abstract: The present invention relates to a novel co-crystal of the compound of formula (I): (Formula (I)) wherein the co-former molecule is bisphosphate hemihydrate, to processes for the preparation of the co-crystal, to pharmaceutical compositions containing the co-crystal, to the use of such a co-crystal in the manufacture of a medicament for use in the treatment of cancer and to methods of treating such diseases in the human or animal body by administering a therapeutically effective amount of such a co-crystal.
-
-
-
-
-
-
-
-
-